Intravenous immunoglobulin protects neurons against amyloid beta-peptide toxicity and ischemic stroke by attenuating multiple cell death pathways

Journal of Neurochemistry

Volumn 122, Issue 2, 2012, Pages 321-332

  Widiapradja, Alexander ^a   Vegh, Viktor ^a   Lok, Ker Zhing ^a   Manzanero, Silvia ^a   Thundyil, John ^a   Gelderblom, Mathias ^b   Cheng, Yi Lin ^a   Pavlovski, Dale ^a   Tang, Sung Chun ^c   Jo, Dong Gyu ^d   Magnus, Tim ^b   Chan, Sic L ^e   Sobey, Christopher G ^f   Reutens, David ^a   Basta, Milan ^g   Mattson, Mark P ^h   Arumugam, Thiruma V ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d Sungkyunkwan University   (South Korea)

^e UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^f MONASH UNIVERSITY   (Australia)

^g BioVisions Inc   (United States)

^h NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

A ; Alzheimer's disease; apoptosis; IVIg; neurons; stroke

Indexed keywords

4 HYDROXYNONENAL; AMYLOID BETA PROTEIN; CASPASE 3; IMMUNOGLOBULIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RELA;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL CULTURE; CELL DEATH; CELL LOSS; CONTROLLED STUDY; DISEASE MODEL; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; INHIBITION KINETICS; LIPID PEROXIDATION; MALE; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UPREGULATION;

AMYLOID BETA-PEPTIDES; ANIMALS; BLOTTING, WESTERN; BRAIN ISCHEMIA; BRAIN MAPPING; CELL DEATH; CELL HYPOXIA; CELL SURVIVAL; GLUCOSE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INFARCTION, MIDDLE CEREBRAL ARTERY; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STROKE; TREATMENT OUTCOME; UP-REGULATION;

MUS;

EID: 84863322930     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2012.07754.x     Document Type: Article

References (47)

1. Alves da Costa C., Mattson M. P., Ancolio K., and, Checler F., (2003) The C-terminal fragment of presenilin 2 triggers p53-mediated staurosporine-induced apoptosis, a function independent of the presenilinase-derived N-terminal counterpart. J. Biol. Chem. 278, 12064-12069. (Pubitemid 36800183)
2. Anthony R. M., Kobayashi T., Wermeling F., and, Ravetch J. V., (2011) Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475, 110-113.
3. Arumugam T. V., Salter J. W., Chidlow J. H., Ballantyne C. M., Kevil C. G., and, Granger D. N., (2004) Contributions of LFA-1 and Mac-1 to brain injury and microvascular dysfunction induced by transient middle cerebral artery occlusion. Am. J. Physiol. Heart Circ. Physiol. 287, H2555-H2560. (Pubitemid 39557124)
4. Arumugam T. V., Tang S. C., Lathia J. D., et al. (2007) Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc. Natl Acad. Sci. USA 104, 14104-14109. (Pubitemid 350003342)
5. Arumugam T. V., Selvaraj P. K., Woodruff T. M., and, Mattson M. P., (2008) Targeting ischemic brain injury with intravenous immunoglobulin. Expert Opin. Ther. Targets 12, 19-29. (Pubitemid 351247159)
6. Arumugam T. V., Woodruff T. M., Lathia J. D., Selvaraj P. K., Mattson M. P., and, Taylor S. M., (2009) Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience 158, 1074-1089.
7. Arumugam T. V., Cheng Y. L., Choi Y., et al. (2011) Evidence that gamma-secretase-mediated Notch signaling induces neuronal cell death via the nuclear factor-kappaB-Bcl-2-interacting mediator of cell death pathway in ischemic stroke. Mol. Pharmacol. 80, 23-31.
8. Aschermann S., Lux A., Baerenwaldt A., Biburger M., and, Nimmerjahn F., (2010) The other side of immunoglobulin G: suppressor of inflammation. Clin. Exp. Immunol. 160, 161-167.
9. Baerenwaldt A., Biburger M., and, Nimmerjahn F., (2010) Mechanisms of action of intravenous immunoglobulins. Expert Rev. Clin. Immunol. 6, 425-434.
10. Basta M., (2008) Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol. Immunol. 45, 4073-4079.
11. Basta M., Langlois P. F., Marques M., Frank M. M., and, Fries L. F., (1989a) High-dose intravenous immunoglobulin modifies complement-mediated in-vivo clearance. Blood 74, 326-333. (Pubitemid 19187448)
12. Basta M., Kirshbom P., Frank M. M., and, Fries L. F., (1989b) Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J. Clin. Invest. 84, 1974-1978.
13. Basta M., Van Goor F., Luccioli S., et al. (2003) F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat. Med. 9, 431-438. (Pubitemid 36460077)
14. Bederson J. B., Pitts L. H., and, Tsuiji M., (1986) Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17, 472-476. (Pubitemid 16085691)
15. Dodel R., Hampel H., Depboylu C., et al. (2002) Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann. Neurol. 52, 253-256. (Pubitemid 34810613)
16. Dodel R. C., Du Y., Depboylu C., et al. (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472-1474. (Pubitemid 39279821)
17. Durandy A., Kaveri S. V., Kuijpers T. W., Basta M., Miescher S., Ravetch J. V., and, Rieben R., (2009) Intravenous immunoglobulins-understanding properties and mechanisms. Clin. Exp. Immunol. 158, Suppl. 1: 2 -13.
18. Fillit H., Hess G., Hill J., Bonnet P., and, Toso C., (2009) IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 73, 180-185.
19. Guan Q. H., Pei D. S., Liu X. M., Wang X. T., Xu T. L., and, Zhang G. Y., (2006) Neuroprotection against ischemic brain injury by SP600125 via suppressing the extrinsic and intrinsic pathways of apoptosis. Brain Res. 1092, 36-46.
20. Inta I., Paxian S., Maegele I., et al. (2006) Bim and Noxa are candidates to mediate the deleterious effect of the NF-kappa B subunit RelA in cerebral ischemia. J. Neurosci. 26, 12896-12903. (Pubitemid 44954609)
21. Kaneko Y., Nimmerjahn F., and, Ravetch J. V., (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673. (Pubitemid 44201145)
22. Keller J. N., and, Mattson M. P., (1998) Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Rev. Neurosci. 9, 105-116. (Pubitemid 28386642)
23. Kotlan B., Stroncek D. F., and, Marincola F. M., (2009) Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science. Immunotherapy 1, 995-1015.
24. Legos J. J., Erhardt J. A., White R. F., et al. (2001) SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia. Brain Res. 892, 70-77. (Pubitemid 32126568)
25. Linnik M. D., Zahos P., Geschwind M. D., and, Federoff H. J., (1995) Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science. Immunotherapy. Stroke 26, 1670-1674.
26. Magga J., Puli L., Pihlaja R., et al. (2010) Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J. Neuroinflammation 7, 90.
27. Mark R. J., Lovell M. A., Markesbery W. R., Uchida K., and, Mattson M. P., (1997) A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J. Neurochem. 68, 255-264. (Pubitemid 26427315)
28. Mattson M. P., (2009) Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders. Exp. Gerontol. 44, 625-633.
29. Mattson M. P., Partin J., and, Begley J. G., (1998) Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res. 807, 167-176. (Pubitemid 29005249)
30. Mattson M. P., Culmsee C., and, Yu Z. F., (2000) Apoptotic and antiapoptotic mechanisms in stroke. Cell Tissue Res. 301, 173-187. (Pubitemid 30459864)
31. Munoz L., and, Ammit A. J., (2010) Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 58, 561-568.
32. Okun E., Arumugam T. V., Tang S. C., et al. (2007) The organotellurium compound ammonium trichloro(dioxoethylene-0,0') tellurate enhances neuronal survival and improves functional outcome in an ischemic stroke model in mice. J. Neurochem. 102, 1232-1241. (Pubitemid 47174227)
33. Paradis E., Douillard H., Koutroumanis M., Goodyer C., and, LeBlanc A., (1996) Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons. J. Neurosci. 16, 7533-7539. (Pubitemid 26389692)
34. Prehn J. H., Bindokas V. P., Marcuccilli C. J., Krajewski S., Reed J. C., and, Miller R. J., (1994) Regulation of neuronal Bcl2 protein expression and calcium homeostasis by transforming growth factor type beta confers wide-ranging protection on rat hippocampal neurons. Proc. Natl Acad. Sci. USA 91, 12599-12603.
35. Ramin M., Azizi P., Motamedi F., Haghparast A., and, Khodagholi F., (2011) Inhibition of JNK phosphorylation reverses memory deficit induced by β-amyloid (1-42) associated with decrease of apoptotic factors. Behav. Brain Res. 217, 424-431.
36. Relkin N. R., Szabo P., Adamiak B., et al. (2009) 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 30, 1728-1736.
37. Sahara N., Murayama M., Lee B., et al. (2008) Active c-jun N-terminal kinase induces caspase cleavage of tau and additional phosphorylation by GSK-3beta is required for tau aggregation. Eur. J. Neurosci. 27, 2897-2906. (Pubitemid 351832217)
38. Samuelsson A., Towers T. L., and, Ravetch J. V., (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291, 484-486. (Pubitemid 32097072)
39. Stine W. B. Jr, Dahlgren K. N., Krafft G. A., and, LaDu M. J., (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem. 278, 11612-11622. (Pubitemid 36792723)
40. 2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp. Neurol. 180, 144-155. (Pubitemid 36398169)
41. Tamatani M., Mitsuda N., Matsuzaki H., et al. (2000) A pathway of neuronal apoptosis induced by hypoxia/reoxygenation: roles of nuclear factor-kappaB and Bcl-2. J. Neurochem. 75, 683-693. (Pubitemid 30485449)
42. Tang S. C., Arumugam T. V., Xu X., et al. (2007) Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc. Natl Acad. Sci. USA 104, 13798-13803. (Pubitemid 350003400)
43. Tang S. C., Lathia J. D., Selvaraj P. K., et al. (2008) Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp. Neurol. 213, 114-121.
44. Thundyil J., Tang S. C., Okun E., et al. (2010) Evidence that adiponectin receptor 1 activation exacerbates ischemic neuronal death. Exp. Transl. Stroke Med. 2, e15.
45. Vukic V., Callaghan D., Walker D., et al. (2009) Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol. Dis. 34, 95-106.
46. Woodruff T. M., Thundyil J., Tang S. C., Sobey C. G., Taylor S. M., and, Arumugam T. V., (2011) Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol. Neurodegener. 6, e11.
47. Yang Z. H., Sun K., Suo W. H., et al. (2010) N-stearoyltyrosine protects primary neurons from Aβ-induced apoptosis through modulating mitogen-activated protein kinase activity. Neuroscience 169, 1840-1847.